The latest Business updates from the science industry
by Heather Hobbs Launch of Medical Isotope Facility will Ease Future Demand
Describing the facility as an important milestone for the company, for Bavaria and for patients, Dr Florian Herrmann, Head of the State Chancellery and Minister of State for Federal Affairs and Media, commented: “As a local member of parliament, I am particularly pleased that the production facility is being built here in Neufahrn near Freising. This is a strong signal for the community and the entire region. As the Free State of Bavaria, we have been supporting the development of ITM practically from the very beginning. The Bavarian Research Foundation has already provided fi nancial support for many of the company’s important research projects. We will continue to support the research and development of innovative cancer drugs in the future. We want Bavaria and Germany to remain international leaders in nuclear medicine in the future.”
ITM opens new production facility, ITM COO Dr Mark Harfensteller, ITM Chaiman of the Board Udo Vetter, Minister of State Dr Florian Herrmann, ITM CEO Steffen Schuster, Mayor Neufahrn Franz Heilmeier
A new 7000 m2 medical isotope facility – the world’s largest production site of lutetium-177, has been opened in Neufahrn, Germany, by ITM Isotope Technologies. The ceremony was conducted by Minister of State, Dr Florian Herrmann in the presence of other high-ranking guests.
Used in targeted cancer therapies, this medical isotope has gained importance in precision oncology treatments in recent years; once the new NOVA production facility is fully operational, ITM will increase its capacity to supply clinics, pharmaceutical partners and its own drug pipeline tenfold, to meet rapidly growing demand.
“Radiopharmaceuticals are an essential new class of anti-cancer drugs that have the potential to improve therapy outcomes and quality of life for many patients. ITM’s additional production site is an important contribution to medical research and drug supply for patients in Germany and worldwide,” said Udo J. Vetter, Chairman of the Supervisory Board of ITM and Chairman of the Advisory Board of Vetter Pharma.
“With the signifi cant expansion of our production capacities we are solidifying our leading market position while, as the world’s largest manufacturer of nca (no carrier added) lutetium-177, supporting the growth of the radiopharmaceutical industry globally, for which we are a driver and a partner. Together, it is our goal to develop and provide innovative diagnostics and therapeutics for the treatment of cancer patients,” added Steffen Schuster, CEO of ITM.” The excellent regional conditions surrounding our facilities coupled with our strong team and established logistics network will enable the fastest possible delivery of high quality radioisotopes to anywhere in the world.”
Minster of State Dr Florian Herrmann with ITM CEO Steffen Schuster at a mock-up hot cell for the production of lutetium-177
ITM’s business was enabled, in part, by years of collaboration with the Garching Research Reactor (FRM II) and the Technical University of Munich (TUM). ITM will operate the new production site at NOVA Neufahrn industrial park in addition to its existing manufacturing facility IAZ at the main site in Garching near Munich.
Operating at industry 4.0 technical level, the facility features a high degree of automation in production and logistics. It offers clean rooms, laboratories and offi ces for use by up to 200 employees for research, radiopharmaceutical manufacturing and aseptic production.
More information online:
ilmt.co/PL/ymZo 60629pr@reply-direct.com
Acquisition Strengthens Position in Niche Markets
The successful acquisition of Eeweka, a highly regarded German developer and manufacturer of tablet testing equipment, has been proudly announced by the Verder Group.
Becoming an integral part of Verder Scientifi c, its complementary technology brings the opportunity to accelerate the division’s trajectory in targeted niche markets. Founded in 1951, Erweka’s manufacturing and assembly facility in Langen, (near Frankfurt) and sales offi ces in the US and Hong Kong, have supplied dissolution and tablet testing equipment to pharmaceutical and life science companies, research and test laboratories and universities all over the world.
Verder Group Founder/Owner and CEO Andries Verder expressed his enthusiasm: “We are excited to welcome Erweka into the Verder family. Its strong market position and exceptional expertise perfectly complement the Verder Scientifi c existing portfolio. Together, we will unlock new possibilities, accelerate innovation and create synergies that benefi t our customers, employees and stakeholders.”
Erweka CEO Claudia Müller stated: “Today (25 May) marks an exciting milestone as our technology driven company joins forces with Verder Scientifi c. Together, we embark on a journey that not only guarantees a future-proof and robust foundation but also unveils unprecedented growth possibilities. Our shared vision is rooted in the belief that technology, when harnessed strategically, can transform lives and businesses alike.”
Dr Jürgen Pankratz, CEO Verder Scientifi c Instruments Division stated: “We will take our time to deeply understand the customer’s needs and dynamics of this new business segment. I have no doubt that subsequently we will jointly derive a business plan that will make signifi cant contributions to the future growth and success of Erweka.”
More information online:
ilmt.co/PL/wvWK 60491pr@reply-direct.com
Pictured from left: Andries Verder, Claudia Müller and Jürgen Pankratz Partnership Delivers on Efficiency with Downstream Manufacturing
A new collaboration to develop integrated analytical solutions to provide robust data for downstream biomanufacturing, has expanded an existing agreement between Waters and Sartorius that initially began with upstream bioprocessing analytics.
“From the beginning of our collaboration with Sartorius, we’ve strived to give bioprocess engineers faster and more direct access to critical quality attribute information about their drug products in the name of improving production yields and getting drugs to patients faster,” said Jon Pratt, Senior Vice President, Waters Division. “Based on the positive response of customers to our collaborative efforts with upstream bioprocessing analytics, we see tremendous benefi t to combining the PATROL Process Analysis System (UPLC) and the
Sartorius BioSMB (multi-column platform) to bring timely point-of- decision analytics to downstream biomanufacturing for monoclonal antibodies, recombinant proteins, vaccines and AAV gene therapies.”
“Now that intensifi ed, continuous manufacturing of biologics is becoming a reality, there is a greater need for real-time analytical measurement,” said René Fáber, Head of Bioprocess Solutions Division, Sartorius. “The value of combining technologies from Sartorius and Waters lies in bringing fundamentally important analytics to the point where it is needed and giving bioprocess engineers a more complete understanding of their downstream manufacturing processing and its effects on drug product quality. We believe this can have signifi cant impacts on drug production
costs by helping to increase yields and reduce waste.”
In-process sampling and the analysis of biological drugs sent to a central laboratory can take weeks before the results of necessary quality checks are in. The combined efforts from Waters and Sartorius have been to show how this process can be streamlined so that product quality tests for protein A, aggregation and charge variants occur closer to the process, with potentially signifi cant reductions in production time.
More information online:
ilmt.co/PL/E3LJ 60626pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
